What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit fell 230.31% in the last year to $118.94 M. Its sector's average net profit growth for the last fiscal year was -33.01%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio is -22.59, which is negative.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit fell 513.2% YoY to $45.6 M. Its sector's average net profit growth YoY for the quarter was -31.14%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE)?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE) for the last financial year was -25.24%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding decreased by 0.67% in the last quarter to 35.62.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding increased by 0.16% in the last quarter to 100.16.

MoonLake Immunotherapeutics - Ordinary Shares - Class A XNAS: MLTX

MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

Name: MoonLake Immunotherapeutics - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: MoonLake Immunotherapeutics - Ordinary Shares - Class A
Rating: 1.23858325
Author: Trendlyne DVM scores

Download real time

42.32 0.88 (2.12%)

25.58% Fall from 52W High

367.4K XNAS Volume

XNAS 02 May, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for MoonLake Immunotherapeutics - Ordinary Shares - Class A is on 07 May 2025 for the purpose of MoonLake Immunotherapeutics First Quarter Earnings Results for 2025 See details

Not Eligible

-

Expensive Valuation

3.3 / 100

Technically Neutral

46.2 / 100

No estimates available

MoonLake Immunotherapeutic... Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

MoonLake Immunotherapeutics - Ordinary Shares - Class A FAQ

How is MoonLake Immunotherapeutics - Ordinary Shares - Class A today?

MoonLake Immunotherapeutics - Ordinary Shares - Class A today is trading in the green, and is up by 2.12% at 42.32.

How has MoonLake Immunotherapeutics - Ordinary Shares - Class A performed historically?

MoonLake Immunotherapeutics - Ordinary Shares - Class A is currently trading up 2.12% on an intraday basis. In the past week the stock rose 7.36%. stock has been down -3.05% in the past quarter and fell -6.50% in the past year. You can view this in the overview section.